Live
BioPharma DiveRallyBio tries again for reverse merger, this time with AvenzoEndpoints NewsThe cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that wayEndpoints NewsEpigenetic editing shows promise against chronic hep B infectionsFierceBiotechASCO, Ryght AI team up for breast cancer trial site selectionClinical OMICsSMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCsClinical OMICsPancreatic Cancer Drug Doubles Survival While Reducing Side EffectsEndpoints NewsShionogi wins US approval for first pill to prevent Covid following exposureEndpoints News#ASCO: Lilly's plenaries; Incyte's frontline data in lymphomaBioPharma DiveServier buys into muscular dystrophy with potentially $2.7B dealBioWorldASCO 2026: A revolution in pancreatic cancerBioWorldBiggest gainers and losers for May 25-29, 2026Endpoints NewsAgios licenses Oscotec drug; CEPI funds three potential Ebola vaccines

Archive

Latest Oldest Clear
@Schunk
Total 25
Source Schunk
Query --